CRSP
CRISPR TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
CRSP vs peer average
72/100
CRSP vs. peer average (B vs. C)
Grade spread
A 1 · B 1 · C 4 · D 3 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
EDIT is the first available peer comparator.
Editas — CRISPR-focused developer with comparable clinical-stage risk and regulatory sensitivity.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
CRSP
CRISPR Therapeutics
EDIT
Editas Medicine
Grade
B
C
Momentum
21
85
Value
41
41
Sentiment
96
45
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Mixed
Grade position vs EDIT
CRSP / EDIT
Grade Position
Above peers
CRSP vs. peer average (B vs. C)
72/100
Momentum
21
EDITValue
41
CRSPSentiment
96
CRSPRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs CRSP
EDIT is the first peer returned for this comparison set.